Examples of 'antagonist antibody' in a sentence
Meaning of "antagonist antibody"
antagonist antibody: A type of antibody that binds to specific molecules known as antigens, and blocks their effects. This term is often used in the field of immunology to describe antibodies that inhibit the actions of other antibodies or immune cells
How to use "antagonist antibody" in a sentence
Basic
Advanced
antagonist antibody
In other embodiments, the antibody is an antagonist antibody.
Antagonist antibody directed against calcitonin gene-related peptide.
Administration of an anti-NGF antagonist antibody.
The anti-NGF antagonist antibody may be as described herein.
Individuals are given incremental dosages of an anti-CGRP antagonist antibody.
Various formulations of an anti-CGRP antagonist antibody may be used for administration.
Individuals are given incremental dosages of an anti-NGF antagonist antibody.
A cell overexpressing the anti-CGRP antagonist antibody of interest can be identified.
At least one active agent in the composition is an anti-NGF antagonist antibody.
Various formulations of an anti-NGF antagonist antibody may be used for administration.
An expression vector can be used to direct expression of an anti-CGRP antagonist antibody.
In one embodiment, the anti-CGRP antagonist antibody acts peripherally on administration.
At least one active agent in the composition is an anti-CGRP antagonist antibody.
An anti-CGRP antagonist antibody for use in the prevention or treatment of cluster headache.
In still other embodiment, the anti-NGF antagonist antibody is a monoclonal antibody.
See also
An expression vector can be used to direct expression of an anti-NGF antagonist antibody.
In one embodiment, an antagonist antibody of the invention disrupts c-met dimerization comprising homodimerization.
Described herein are nucleic acids encoding a beta7 antagonist antibody of the invention.
The anti-CGRP antagonist antibody can be administered to an individual vÃa any suitable route.
In another embodiment, the composition comprises one or more anti-NGF antagonist antibody.
Preferably the anti-CGRP antagonist antibody is isolated, further preferably it is substantially pure.
In one aspect, the invention provides nucleic acids encoding a beta7 antagonist antibody of the invention.
A beta7 antagonist antibody may specifically binds a sequence in the ligand binding domain of beta7.
In one aspect, the invention provides nucleic acids encoding a c-met antagonist antibody of the invention.
In one embodiment, the anti-CGRP antagonist antibody is effective in treating refractory pain populations.
It is understood that the compositions can comprise more than one anti-NGF antagonist antibody antagonist.
In some embodiments, the anti-CGRP antagonist antibody comprises a modified constant region as described herein.
NGF antagonists The invention utilizes an anti-NGF antagonist antibody.
In some embodiments, the anti-NGF antagonist antibody is not associated with an adverse immune response.
In one embodiment, the composition comprises an anti-NGF antagonist antibody.
In some embodiments, the anti-CGRP antagonist antibody may be humanized but is more preferably human.
An antagonist antibody of the polypeptide of any one of claims 1 to 10.
In certain embodiments, the neutralising antibody is an antagonist antibody to a chemokine receptor CCX-CKR.
Anti-NGF antagonist antibody may be administered to an individual vÃa any suitable route.
In yet other embodiments, the anti-NGF antagonist antibody specifically binds human NGF.
An antagonist antibody described herein may decrease at least one activity of ErbB2 by 5-fold.
In some embodiments, the anti-NGF antagonist antibody specifically binds to the NGF molecule.
Treatment of leukemia with a Notch1-specific antagonist antibody.
In one embodiment, the anti-CGRP antagonist antibody inhibits or prevents activation of the CGRP receptor.
In certain embodiments, the Notch1-specific antagonist that is administered is an anti-Notch1 antagonist antibody.
In some embodiments, the anti-CGRP antagonist antibody is isolated.
The anti-CGRP antagonist antibody may be administered prior to, during and / or after headache.
Humanization of a beta7 Antagonist Antibody.
In one embodiment, a beta7 antagonist antibody of the invention disrupts binding of alpha4beta7 to MAdCAM.
In still other embodiments, the anti-CGRP antagonist antibody is humanized.
In one embodiment, a beta7 antagonist antibody of the invention disrupts binding alphaEbeta7 integrin to E-cadherin.
In some embodiments, the anti-CGRP antagonist antibody is human.
Mouse anti-NGF antagonist antibody 911 was also tested, and similar results were observed.
In some embodiments, the anti-CGRP antagonist antibody is humanized.
In one embodiment, a beta7 antagonist antibody of the invention disrupts binding of beta7 to alphaE.
You'll also be interested in:
Examples of using Antibody
Show more
Antibody status should be monitored and reported
The kinetics of antibody decline are also similar
Antibody persistence after booster immunisation adults
Examples of using Antagonist
Show more
You are the final antagonist in the game
Antagonist drugs could provide better recover
Who is the principal antagonist in the strike
